Other substances

Linolenic acid

An omega-3 fatty acid.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Natural product

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Linolenic acid is an essential omega-3 fatty acid with anti-inflammatory properties (NCIt).

Linolenic acid on DrugBank
Linolenic acid on PubChem
Linolenic acid on Wikipedia

Synonyms

α-Linolenic acid; ALA

CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Polyunsaturated ω-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry Spike protein ACE2 TMPRSS2 Cathepsin L Small molecule In vitro	A549/hACE2 cells; (rVSV) SARS-CoV-2 Spike pseudovirus	4.00	The fatty acid blocked SARS-CoV-2 Spike protein pseudovirus entry into cells in vitro. It impeded RBD binding to host ACE2 receptor and reduced the activity (but not protein levels) of TMPRSS2 and cathepsin L proteases.	Mar/04/2021

AI-suggested references

Link	Publication date
Therapeutic potential of 5-aminolevulinic acid and sodium-ferrous citrate for viral insults: relevance to the COVID-19 crisis.	Dec/30/2021
Isolation and characterization of ACE-I inhibitory peptides from ribbonfish for a potential inhibitor of the main protease of SARS-CoV-2; an in-silico analysis.	Dec/13/2021
A Combination of alpha-Lipoic Acid (ALA) and Palmitoylethanolamide (PEA) Blocks Endotoxin-Induced Oxidative Stress and Cytokine Storm: A Possible Intervention for COVID-19.	Nov/09/2021
Neuropilin-1 is a host factor for SARS-CoV-2 infection.	Jun/15/2020
Perspectives on plant flavonoid quercetin-based drugs for novel SARS-CoV-2.	Mar/24/2021
Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection.	Aug/14/2020
Polyunsaturated omega-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry	Mar/04/2021
5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro	Apr/27/2022
Natural products may interfere with SARS-CoV-2 attachment to the host cell	Oct/29/2021
Critical Sequence Hotspots for Binding of Novel Coronavirus to Angiotensin Converter Enzyme as Evaluated by Molecular Simulations	Dec/07/2020
Structure-Guided Mutagenesis Alters Deubiquitinating Activity and Attenuates Pathogenesis of a Murine Coronavirus	Mar/19/2021
Genomic diversity and molecular dynamics interaction on mutational variances among RB domains of SARS-CoV-2 interplay drug inactivation	May/07/2020
Thermostable designed ankyrin repeat proteins (DARPins) as building blocks for innovative drugs	Jun/30/2021
PASylated Thymosin alpha1: A Long-Acting Immunostimulatory Peptide for Applications in Oncology and Virology	May/21/2020
A Randomized, Single-Blind, Group Sequential, Active-Controlled Study to Evaluate the Clinical Efficacy and Safety of alpha-Lipoic Acid for Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)	Feb/04/2022
Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2	Sep/24/2020
Targeting SARS-CoV-2 with Chaga mushroom: An in silico study toward developing a natural antiviral compound	Oct/20/2021
Antiviral Peptides as Promising Therapeutics against SARS-CoV-2	Oct/23/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04604743	Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama	Recruiting	Not Applicable	Apr/20/2021	Jun/30/2023
Alternative id - MISP #60590 Interventions - Behavioral: Intervention, TBN Study type - Interventional Study results - No Results Available Locations - University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 4 Age - 15 Years to 17 Years (Child) Outcome measures - HPV Vaccination\|Reduction in Vaccine Hesitancy
NCT04703036	Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19	Recruiting	Early Phase 1	Jan/11/2021	Dec/31/2023
Alternative id - H48057 Interventions - Dietary Supplement: Glycine\|Dietary Supplement: N-acetylcysteine\|Dietary Supplement: Alanine Study type - Interventional Study results - No Results Available Locations - Baylor College of Medicine, Houston, Texas, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Other Enrollment - 64 Age - 55 Years to 85 Years (Adult, Older Adult) Outcome measures - Change in Glutathione concentrations\|Change in Interleukein 6 concentrations\|Change in Ordinal scale\|Change in oxidative stress\|Change in marker of damage due to oxidative stress\|Change in inflammatory cytokines\|Change in mitochondrial energetics\|Change in immune function\|Change in cognition\|Change in function\|Change in fatigue\|Change in circulating marker of memory
NCT04405271	TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)	Not yet recruiting	Phase 3	Jul/31/2020	Nov/15/2020
Alternative id - 5616 Interventions - Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Sociedad Argentina de Infectología, A. J. Carranza 974, Ciudad Autonoma de Buenos Aires, Capital Federal, Argentina Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 1378 Age - 18 Years and older (Adult, Older Adult) Outcome measures - COVID-19 incident cases\|Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology\|Severity of symptomatic COVID-19\|Respiratory symptom duration in days\|Relation between treatments and symptoms duration\|Time course of specific IgM/IgG seroconversion

Export (.csv)